Predictive digital twin for optimizing patient-specific radiotherapy regimens under uncertainty in high-grade gliomas

被引:17
|
作者
Chaudhuri, Anirban [1 ]
Pash, Graham [1 ]
Hormuth II, David A. [1 ,2 ]
Lorenzo, Guillermo [1 ,3 ]
Kapteyn, Michael [1 ]
Wu, Chengyue [1 ]
Lima, Ernesto A. B. F. [1 ,4 ]
Yankeelov, Thomas E. [1 ,2 ,5 ,6 ,7 ,8 ]
Willcox, Karen [1 ]
机构
[1] Univ Texas Austin, Oden Inst Computat Engn & Sci, Austin, TX 78712 USA
[2] Univ Texas Austin, Livestrong Canc Inst, Austin, TX 78705 USA
[3] Univ Pavia, Dept Civil Engn & Architecture, Pavia, Italy
[4] Univ Texas Austin, Texas Adv Comp Ctr, Austin, TX USA
[5] Univ Texas Austin, Dept Biomed Engn, Austin, TX USA
[6] Univ Texas Austin, Dept Diagnost Med, Austin, TX USA
[7] Univ Texas Austin, Dept Oncol, Austin, TX USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX USA
来源
关键词
digital twin; risk-aware clinical decision-making; personalized tumor forecasts; uncertainty quantification; adaptive radiotherapy; mathematical oncology; brain cancer; ADAPTIVE RADIOTHERAPY; RADIATION; GLIOBLASTOMA; OPTIMIZATION; MODELS; FUTURE;
D O I
10.3389/frai.2023.1222612
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
We develop a methodology to create data-driven predictive digital twins for optimal risk-aware clinical decision-making. We illustrate the methodology as an enabler for an anticipatory personalized treatment that accounts for uncertainties in the underlying tumor biology in high-grade gliomas, where heterogeneity in the response to standard-of-care (SOC) radiotherapy contributes to sub-optimal patient outcomes. The digital twin is initialized through prior distributions derived from population-level clinical data in the literature for a mechanistic model's parameters. Then the digital twin is personalized using Bayesian model calibration for assimilating patient-specific magnetic resonance imaging data. The calibrated digital twin is used to propose optimal radiotherapy treatment regimens by solving a multi-objective risk-based optimization under uncertainty problem. The solution leads to a suite of patient-specific optimal radiotherapy treatment regimens exhibiting varying levels of trade-off between the two competing clinical objectives: (i) maximizing tumor control (characterized by minimizing the risk of tumor volume growth) and (ii) minimizing the toxicity from radiotherapy. The proposed digital twin framework is illustrated by generating an in silico cohort of 100 patients with high-grade glioma growth and response properties typically observed in the literature. For the same total radiation dose as the SOC, the personalized treatment regimens lead to median increase in tumor time to progression of around six days. Alternatively, for the same level of tumor control as the SOC, the digital twin provides optimal treatment options that lead to a median reduction in radiation dose by 16.7% (10 Gy) compared to SOC total dose of 60 Gy. The range of optimal solutions also provide options with increased doses for patients with aggressive cancer, where SOC does not lead to sufficient tumor control.
引用
收藏
页数:20
相关论文
共 8 条
  • [1] Patient experiences in high-grade gliomas: from symptoms to radiotherapy
    Chainey, Jonathan
    Kim, Michael J.
    Chan, Vivien Ka-Ying
    Au, Karolyn
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2024,
  • [2] Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma
    Glazar, Daniel J.
    Grass, G. Daniel
    Arrington, John A.
    Forsyth, Peter A.
    Raghunand, Natarajan
    Yu, Hsiang-Hsuan Michael
    Sahebjam, Solmaz
    Enderling, Heiko
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 11
  • [3] EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL
    Glazar, Daniel
    Brady, Rene
    Howard, Rachel
    Grass, Daniel
    Arrington, John
    Yu, Michael
    Raghunand, Natarajan
    Sahebjam, Solmaz
    Enderling, Heiko
    NEURO-ONCOLOGY, 2019, 21 : 63 - 64
  • [4] Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF- β Small Molecule Inhibitor1,2
    Bayin, N. Sumru
    Ma, Lin
    Thomas, Cheddhi
    Baitalmal, Rabaa
    Sure, Akhila
    Fansiwala, Kush
    Bustoros, Mark
    Golfinos, John G.
    Pacione, Donato
    Snuderl, Matija
    Zagzag, David
    Barcellos-Hoff, Mary Helen
    Placantonakis, Dimitris
    NEOPLASIA, 2016, 18 (12): : 795 - 805
  • [5] Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein
    Crane, Courtney A.
    Han, Seunggu J.
    Ahn, Brian
    Oehlke, Jessica
    Kivett, Valerie
    Fedoroff, Anne
    Butowski, Nicholas
    Chang, Susan M.
    Clarke, Jennifer
    Berger, Mitchel S.
    McDermott, Michael W.
    Prados, Michael D.
    Parsa, Andrew T.
    CLINICAL CANCER RESEARCH, 2013, 19 (01) : 205 - 214
  • [6] Predictive value of clone-specific CDR3 PCR in high-grade non-Hodgkin's lymphoma: Long-term persistence of a clone-specific rearrangement in a patient with secondary high-grade NHL in remission after high-dose therapy
    Scholten, C
    Hilgarth, B
    Hilgarth, M
    Jaeger, U
    Greinix, HT
    Mannhalter, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (01) : 246 - 247
  • [7] A DEEP LEARNING-BASED METHOD FOR RAPID, PATIENT-SPECIFIC ASSAY OF MACROPHAGE INFILTRATION IN HIGH-GRADE GLIOMA USING LABEL-FREE STIMULATED RAMAN HISTOLOGY.
    Alber, Daniel
    Lock, Emily
    Sangwon, Karl
    Smith, Andrew
    Movahed-Ezazi, Misha
    Oermann, Eric
    Hollon, Todd
    Orringer, Daniel
    NEURO-ONCOLOGY, 2023, 25
  • [8] Precision Medicine with TGF-β Inhibition Using Tumor Explants: Comment on "Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor" by N. Sumru Bayin et al.
    Huang, Haidong
    Yu, Jennifer S.
    NEOPLASIA, 2016, 18 (12): : 806 - 807